{
  "filename": "Module 1_Slides 0.1.pptx",
  "slide_count": 16,
  "slides": [
    {
      "slide_number": 1,
      "texts": [
        {
          "text": "DMD Management",
          "is_title": true
        },
        {
          "text": "Nadia Merchant, MD\nAssistant Professor of Pediatrics\nPediatric Endocrinologist and Geneticist\n ",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 2,
      "texts": [
        {
          "text": "Disclosures",
          "is_title": true
        },
        {
          "text": "Growth Advisory Board for BioMarin, Pfizer and Alexion \nNo relevant financial disclosures for this presentation",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 3,
      "texts": [
        {
          "text": "Corticosteroid management\n",
          "is_title": false
        },
        {
          "text": "Management of DMD is Multidisciplinary ",
          "is_title": false
        },
        {
          "text": "Management should be provided bu a patient-oriented mulidisciplinary team\n\nRealistic therapeutic plan should be established with the patient and his family\n\nPatient should be assessed every 6 monhs and get full assesment every year\n\nAccess to first line care should be organised.\n\nPrevention of disese next milestone should always be prioritized",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 4,
      "texts": [
        {
          "text": "Why corticosteroids?",
          "is_title": true
        },
        {
          "text": "Delayed loss of ambulation\nPreserved upper limb function\nReduced scoliosis surgery\nImproved cardiopulmonary function",
          "is_title": false
        },
        {
          "text": "Neurology\nCorticosteroid management\nPrednisone, Deflazacort, Vamorolone \nExon skipping\nGene therapy\n",
          "is_title": false
        },
        {
          "text": "All or most new treatments are used or investigated in combination with corticosteroids",
          "is_title": false
        },
        {
          "text": "Management of DMD is Multidisciplinary ",
          "is_title": false
        },
        {
          "text": "Suggestion for LS: add a SOC slide ahead of this one and complete with the clip from webcast",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 5,
      "texts": [
        {
          "text": "Respiratory management",
          "is_title": true
        },
        {
          "text": "Prevention \nChronic Management\nAcute management",
          "is_title": false
        },
        {
          "text": "Most issues happen after loss of ambulation- although prevention and management should start before\nKey mechanisms \n\t\tAlveolar hypoventilation\n\t\tCough insufficiency\n\t\tRisk of aspiration (bulbar weakness- cough insufficiency)\n\t\tRisk of infection (steroids- aspiration-cough insufficiency-atelectasia)\n\t\tRisk of atelectasia (infection- hypoventilation\n",
          "is_title": false
        }
      ],
      "shapes": [
        {
          "type": "image",
          "name": "Image 5"
        }
      ]
    },
    {
      "slide_number": 6,
      "texts": [
        {
          "text": "Prevention & Chronic Management",
          "is_title": true
        },
        {
          "text": "Vaccination : Full vaccination (except live vaccine if on steroids) + Pneumo23+Influenza+Covid19 \nMonitoring of pulmonary function (PFE) and nucturnal ventilation (sleep studies with pCO2 measure)\nInitiation of nocturnal BPAP when needed\nChest physiotherapy : \n\tCough : Manually assisted cough \n\tInspiration ; Lung Volume recruitment- Breath Stacking\n\tExpiration : Mechanical insuflation-exsuflation devices\nPut in place a plan for acute care and discuss limit of care (intubation…)",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 7,
      "texts": [
        {
          "text": "Acute Management",
          "is_title": true
        },
        {
          "text": "Empirical Antibiotic treatment\nManual assisted cough and Mechanical insuflation-exsuflation device\nNon invasive ventilation with BPAP- and adjusting the pressure\nMonitoring of pC02\nAvoiding passive Oxygen \nCardiac-digesgtive-endocrine management\nIf atelectasia- consider the need of bronchoscopy \nIf not sufficient- consider intubation\n",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 8,
      "texts": [
        {
          "text": "Cardiac management",
          "is_title": true
        },
        {
          "text": "Annual assesment through heart ultrasound in infants- cardiac MRI in teenagers + EEG\n\nACE-Inhibitors at the age of 8-10 year. Ex : Captopril 2.5 mg\n\tIf not well tolerated : consider Losartan\nEplerenone or Spironolactone 50 pg daily\nIn case of mild to moderate dysfunction : Beta-blocker (ex : carvedilol)\nSacubitril/Vasartran can be an option in severe case",
          "is_title": false
        }
      ],
      "shapes": [
        {
          "type": "image",
          "name": "Image 4"
        },
        {
          "type": "image",
          "name": "Image 6"
        },
        {
          "type": "image",
          "name": "Image 8"
        },
        {
          "type": "image",
          "name": "Image 10"
        },
        {
          "type": "image",
          "name": "Image 12"
        },
        {
          "type": "image",
          "name": "Image 14"
        }
      ]
    },
    {
      "slide_number": 9,
      "texts": [
        {
          "text": "Steroids- which one- how much-when….",
          "is_title": true
        },
        {
          "text": "Starting before the age of 5 years (but when exactly ?) is more efficient\nDose between 0.3-0.9 mg/kg with some evidence of dose effect\nSuperiority of Deflazacort on Prednisone is controversial- some evidence points to a better efficacy- some not.\nDifferent regimen exist: Daily dose   One day on-One day off   10 days on-10 days off….\nDaily dose seems more efficient but associated with more side effects.\n",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 10,
      "texts": [
        {
          "text": "Steroids in my practice",
          "is_title": true
        },
        {
          "text": "Start around the age of 3- when vaccination is completed (Chicken pox !)\nExplain the importance of healthy diet before starting- and ideally around diagnostic\nStart slowly with 1mg of DFZ to increase every 5 days- up to 0.9mg/Kg \nIf the patient presents with behavioural issue- stop increasing and keep with the highest well-tolerated dose. Try to increase again slowly three months later\nKeep with daily dose if well-tolerated. Consider one day on/one day off if unmanageable side effect- or when growth delay become an issue \n",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 11,
      "texts": [
        {
          "text": "Orthopaedic management",
          "is_title": true
        },
        {
          "text": "Prevention of contracture : exercise/stretching/Splints…\nSurgery of contracures are rarely indicated (only if significant functional benefit to be expected)\nIn case of fracture- prioritze fixation and mobilisation when possible rahter than long casting immobilization\nScoliosis surgery when Cobb angle > 40 and Vital capacity > 40%",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 12,
      "texts": [],
      "shapes": [
        {
          "type": "image",
          "name": "Espace réservé du contenu 4"
        }
      ]
    },
    {
      "slide_number": 13,
      "texts": [
        {
          "text": "Steroids",
          "is_title": false
        },
        {
          "text": "Hormones/\nPuberty",
          "is_title": false
        },
        {
          "text": "Physical Activity \n(Mechanosensors in bone for bone modeling and remodeling)",
          "is_title": false
        },
        {
          "text": "Chronic \nDisease = DMD",
          "is_title": false
        },
        {
          "text": "Nutrition and Diet\n(Vitamin D/Calcium)",
          "is_title": false
        },
        {
          "text": "We all play a role in maximizing bone health and quality of life!",
          "is_title": true
        },
        {
          "text": "Suggestion for LS: to create an orthopaedic slide to add after this one",
          "is_title": false
        },
        {
          "text": "Alba to use the reference to create descriptive text for this slide",
          "is_title": false
        }
      ],
      "shapes": [
        {
          "type": "image",
          "name": "Picture 3"
        }
      ]
    },
    {
      "slide_number": 14,
      "texts": [
        {
          "text": "Monitoring Side Effects of Glucocorticoid Treatment: Refer to endocrine  ",
          "is_title": true
        },
        {
          "text": "Bone Health/Risk for Osteoporosis: \nDXA scan annually along with spine assessment for fractures  \nCalcium and vitamin D intake/supplement, monitoring labs when appropriate \nVitamin D Level (goal >30 ng/dL) \n\nPuberty/Risk for Delayed/Arrested Puberty\nMonitor for puberty delay\nConsider starting testosterone, important for bone health\nTestosterone replacement for all boys > 14 with confirmed hypogonadism, can be considered starting as early as 12 years.\nEvaluate with bone age, LH, FSH, testosterone \nGradually increase testosterone \nAdrenal Insufficiency: \nDue to taking  chronic  steroids, risk for adrenal insufficiency\nNeed a sick day plan along with emergency steroids \n\nWeight Management\nNutrition\nMetabolic screening\nHyperglycemia: History: polyuria, polydipsia, dietary history.  Annual random blood glucose and A1C \nHypertension:  Blood pressure should be monitored at each clinic visit (at least every 6 months)\nDyslipidemia: Lipid panel annually  \nWeight gain with steroids\nObstructive sleep apnea symptoms and evaluation as recommended \n\nGrowth/Risk for Impaired Growth: \nMonitor growth\nEvaluate when appropriate for other causes of impaired growth (CBC, CMP, celiac, thyroid)\nGrowth hormone is not recommended, can be considered case by case\n\n\n",
          "is_title": false
        },
        {
          "text": "Alba to use the reference to create descriptive text for this slide and complete with clip from webcast",
          "is_title": false
        }
      ],
      "shapes": []
    },
    {
      "slide_number": 15,
      "texts": [
        {
          "text": "New therapies and potential improvement",
          "is_title": true
        },
        {
          "text": "Vamorolone has the potential to achieve a similar efficacy than prednisone with less adverse event\n\n\nGivinostat can slow down the decline of ambulation in patients older than 6 years\n\n\nThe effect of AAV-microdystrophin gene therapy is still unclear but could slightly improve motor function in 4-7 year old kid",
          "is_title": false
        }
      ],
      "shapes": [
        {
          "type": "image",
          "name": "Image 4"
        },
        {
          "type": "image",
          "name": "Image 6"
        }
      ]
    },
    {
      "slide_number": 16,
      "texts": [
        {
          "text": "Ward LM, Weber DR. Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy. Curr Opin Endocrinol Diabetes Obes. 2019 Feb;26(1):39-48. doi: 10.1097/MED.0000000000000456. PMID: 30507696; PMCID: PMC6402320.\nBirnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347-361. doi:10.1016/S1474-4422(18)30025-5\nBirnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management [published correction appears in Lancet Neurol. 2018 Apr 4;:]. Lancet Neurol. 2018;17(3):251-267. doi:10.1016/S1474-4422(18)30024-3\nWeber DR, Hadjiyannakis S, McMillan HJ, Noritz G, Ward LM. Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 2018;142(Suppl 2):S43-S52. doi:10.1542/peds.2018-0333F",
          "is_title": false
        }
      ],
      "shapes": []
    }
  ]
}